ACA
ANIP icon

AYAL Capital Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

AYAL Capital Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-60,000
Closed -$3.92M – 46
2025
Q2 		$3.92M Sell
60,000
-6,715
-10% -$437K 0.94% 40
2025
Q1 		$4.47M Buy
+66,715
New +$3.98M 1.48% 25

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

AYAL Capital Advisors's ANIP Position: Q3 2025 in Review

AYAL Capital Advisors sold out of ANI Pharmaceuticals (ANIP) in Q3 2025, closing a stake of 60,000 shares — an estimated $3.92M sold.

AYAL Capital Advisors first reported a position in ANIP in Q1 2025 and held it in 2 quarters. The position peaked at $4.47M in Q1 2025. 269 funds tracked by Wall St. Rank hold ANIP as of Q3 2025.

  • AYAL Capital Advisors reported no remaining ANI Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • AYAL Capital Advisors sold 60,000 ANI Pharmaceuticals shares in Q3 2025, an estimated $3.92M.
  • AYAL Capital Advisors first reported a position in ANI Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • AYAL Capital Advisors's ANI Pharmaceuticals position peaked at $4.47M in Q1 2025.
  • 269 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2025.

Based on AYAL Capital Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.